ProCE Banner Activity

Study 1824: Virologic Suppression Maintained in Patients With M184V/I Mutation After Switch to EVG/COBI/FTC/TAF

Capsule Summary
Conference Coverage

Mutation associated with resistance to lamivudine and emtricitabine did not appear to affect efficacy of switch strategy.

Released: July 25, 2018

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

ProCE Banner

Supporters

Janssen

ViiV Healthcare

Partners

AIDS 2018

ProCE Banner

IAS 2018

ProCE Banner